Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons
Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.
6-Sep-2018 1:15 PM EDT Add to Favorites
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published...
5-Sep-2018 11:40 AM EDT Add to Favorites
Synthetic DNA Technology Provides a Novel Strategy for Effective Delivery of a Complex Anti-HIV Agent
Wistar scientists have applied their synthetic DNA technology to engineer a novel eCD4-Ig anti-HIV agent and to enhance its potency in vivo, providing a new simple strategy for constructing complex therapeutics for infectious agents as well as for...
4-Sep-2018 1:05 PM EDT Add to Favorites
Wistar received more than $5.5 million in grants and awards from local foundations, and national and international funding agencies to support research, education and training at the Institute.
7-Aug-2018 2:45 PM EDT Add to Favorites
Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.
12-Jun-2018 3:30 PM EDT Add to Favorites
The Wistar Institute and Harbour BioMed Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases
Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
4-Jun-2018 12:05 PM EDT Add to Favorites
Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization
Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of...
27-Apr-2018 12:05 PM EDT Add to Favorites
Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in...
25-Apr-2018 12:05 PM EDT Add to Favorites
see all news
Dr. Luis Montaner, Wistar Institute HIV/AIDS Expert, Can Address His Work in the Search for a Cure, for World AIDS Day
26-Nov-2013 2:25 PM EST
22-Feb-2013 4:15 PM EST
The Winter Sun May Not Be Warm, but Still Can Be Dangerous. Wistar Melanoma Expert on Wintertime UV Risks
22-Jan-2013 2:30 PM ESTsee all experts